Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 844

1.
2.

Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.

Westin J, Lindh M, Nenonen N, Lagging LM, Norkrans G, Wejstål R.

Scand J Infect Dis. 2001;33(2):110-5.

PMID:
11233844
3.

Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.

Huang JF, Yu ML, Lee CM, Dai CY, Hou NJ, Hsieh MY, Wang JH, Lu SN, Sheen IS, Lin SM, Chuang WL, Liaw YF.

Aliment Pharmacol Ther. 2007 May 1;25(9):1029-37.

4.

Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.

Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T, Nakano S, Hayashi K, Katano Y, Nakano I, Hayakawa T, Nishimura D, Kato K, Imada K, Imoto M, Fukuda Y; Yon-Ken HCV-HCC Follow-up Study Group.

J Viral Hepat. 2000 Nov;7(6):414-9.

PMID:
11115052
5.

Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death.

Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N.

J Viral Hepat. 2004 Mar;11(2):148-56.

PMID:
14996350
6.

Chronic hepatitis C virus infection in renal transplant: treatment and outcome.

Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.

Clin Transplant. 2006 Nov-Dec;20(6):677-83.

PMID:
17100715
7.

Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.

Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H.

J Gastroenterol. 2005 Feb;40(2):148-56.

PMID:
15770398
8.

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.

Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR.

Hepatology. 2001 Mar;33(3):704-7.

PMID:
11230751
9.

Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.

Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N.

J Viral Hepat. 2010 Mar;17(3):185-91. doi: 10.1111/j.1365-2893.2009.01163.x. Epub 2009 Aug 26.

PMID:
19709362
10.

Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.

Soriano V, Núñez M, Sánchez-Conde M, Barreiro P, García-Samaniego J, Martín-Carbonero L, Romero M, González-Lahoz J.

Antivir Ther. 2005;10(1):167-70.

PMID:
15751774
11.

Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan.

Lai MY.

Intervirology. 2006;49(1-2):91-5. Review.

PMID:
16166795
12.

Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

Omata M, Yoshida H, Shiratori Y.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S141-3. Review.

PMID:
16234063
13.

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.

Imazeki F, Yokosuka O, Fukai K, Saisho H.

Hepatology. 2003 Aug;38(2):493-502.

PMID:
12883494
14.

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.

Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, Sakaguchi H, Kuroda T, Kioka K, Kim SR, Kanno T, Ueda T, Hirano M, Fujimoto S, Jomura H, Nishiguchi S, Seki S.

Liver Int. 2007 Mar;27(2):186-91.

PMID:
17311612
16.

Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.

Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H.

J Gastroenterol Hepatol. 2005 May;20(5):752-8.

PMID:
15853990
17.

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.

Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK.

Clin Gastroenterol Hepatol. 2010 Feb;8(2):192-9. doi: 10.1016/j.cgh.2009.10.026. Epub 2009 Oct 30. Review.

PMID:
19879972
18.

Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.

Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H.

Intervirology. 2007;50(1):16-23.

PMID:
17164553
19.

Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.

Imai Y, Kasahara A, Tanaka H, Okanoue T, Hiramatsu N, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Sasaki Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N.

J Gastroenterol. 2004 Nov;39(11):1069-77.

PMID:
15580400
20.

Long-term cohort study of chronic hepatitis C according to interferon efficacy.

Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O.

J Gastroenterol Hepatol. 2012 Feb;27(2):291-9. doi: 10.1111/j.1440-1746.2011.06871.x.

PMID:
21793911

Supplemental Content

Support Center